Medigene AG to participate at upcoming conferences

Planegg/Martinsried, November 2, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the 29th Annual BIO-Europe taking place November 6-8, 2023, in Munich and present at the Deutsches Eigenkapitalforum to be held November 27-29, 2023, in Frankfurt.

BIO-Europe 2023
Date: November 6-8, 2023
Location: Trade Fair Center Messe München
Members of Medigene’s Corporate Development team will be available for one-on-one meetings at the event.


Corporate presentation – Deutsches Eigenkapitalforum 2023
Date and time: Monday, November 27, 2023, 2:05 pm – 2:35 pm (local time), conference room London
Location: Steigenberger Airport Hotel Frankfurt


Members of Medigene’s management team will be available for one-on-one meetings at the event.
Please contact Julia von Hummel of MC Services at to schedule a meeting at either one of the conferences.


—  end of press release  —


About Medigene AG

Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. Its End-to-End Platform, built on multiple proprietary and exclusive TCR generation and optimization, as well as product enhancement technologies, allows Medigene to create best-in-class, differentiated T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for safety, efficacy and durability. For more information, please visit:


Pamela Keck
Phone: +49 89 2000 3333 01


In case you no longer wish to receive any information about Medigene, please inform us by e-mail ( We will then delete your address from our distribution list.